Efficacy and Safety of Radiotherapy Combined with Immunotherapy for Brain Metastases from Lung Cancer: A Meta-analysis
| Autor: | Lijuan XU, Yingtai CHEN, Mei WANG |
|---|---|
| Jazyk: | čínština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Chinese Journal of Lung Cancer, Vol 25, Iss 10, Pp 715-722 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1009-3419 1999-6187 |
| DOI: | 10.3779/j.issn.1009-3419.2022.101.48 |
| Popis: | Background and objective Immunotherapy (IT) is recommended for the treatment of advanced non-small cell lung cancer (NSCLC), while brain radiotherapy (RT) is the mainstream treatment for patients with brain metastases (BM). This study aimed to investigate the efficacy and safety of combined use of RT and IT. Methods The date was limited to May 1, 2022, and literature searches were carried out in CNKI, Wanfang, PubMed, EMBASE and Cochrane databases. Heterogeneity was judged using the I2 test and P value. Publication bias was assessed using a funnel plot. The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analysis was performed using Stata 16.0 software. Results A total of 17 articles involving 2,636 patients were included. In the comparison of RT+IT group and RT group, no significant difference was found in overall survival (OS) (HR=0.85, 95%CI: 0.52-1.38, I2=73.9%, Pheterogeneity=0.001) and intracranial distance control (DBC) (HR=1.04, 95%CI: 0.55-1.05, I2=80.5%, Pheterogeneity |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|